Platinum Resistance After PARPi Resistance in a gBRCAmt Recurrent Ovarian Cancer Patient: a Case Report-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Platinum Resistance After PARPi Resistance in a gBRCAmt Recurrent Ovarian Cancer Patient: a Case Report

Published:2022-08-09 Issue:2 Volume:30 Page:615-621
ISSN:1933-7191
Container-title:Reproductive Sciences
language:en
Short-container-title:Reprod. Sci.

Author:

Zhao Qian,Ni Jing,Dong Jiayin,Cheng Xianzhong,Xiao Li,Xue Qi,Xu Xia,Guo Wenwen,Chen Xiaoxiang^ORCID

Funder

National Natural Science Foundation of China

Jiangsu Provincial Scientific research and Health Project for Women and Children

Jiangsu Cancer Hospital

Beijing Kanghua Foundation for the Development of Traditional Chinese and Western Medicine -Le Fund

Publisher

Springer Science and Business Media LLC

Subject

Obstetrics and Gynecology

Link

https://link.springer.com/content/pdf/10.1007/s43032-022-01037-3.pdf

Reference20 articles.

1. Lheureux S, Gourley C, Vergote I, Oza AM. Epithelial ovarian cancer. Lancet. 2019;393(10177):1240–53. https://doi.org/10.1016/s0140-6736(18)32552-2.

2. Tan DS, Kaye SB. Chemotherapy for patients with BRCA1 and BRCA2-mutated ovarian cancer: same or different? Am Soc Clin Oncol Educ Book. 2015;114-21. https://doi.org/10.14694/EdBook_AM.2015.35.114

3. Chen Q, Li X, Zhang Z, Wu T. Systematic review of olaparib in the treatment of recurrent platinum sensitive ovarian cancer. Front Oncol. 2022;12:858826. https://doi.org/10.3389/fonc.2022.858826.

4. Agarwal A, Baghmar S, Dodagoudar C, Qureshi S, Khurana A, Vaibhav V, et al. PARP inhibitor in platinum-resistant ovarian cancer: single-center real-world experience. JCO Glob Oncol. 2021;7:506–11. https://doi.org/10.1200/GO.20.00269.

5. Ledermann JA, Drew Y, Kristeleit RS. Homologous recombination deficiency and ovarian cancer. Eur J Cancer. 2016;60:49–58. https://doi.org/10.1016/j.ejca.2016.03.005.

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. MITO39: Efficacy and Tolerability of Pegylated Liposomal Doxorubicin (PLD)–Trabectedin in the Treatment of Relapsed Ovarian Cancer after Maintenance Therapy with PARP Inhibitors—A Multicenter Italian Trial in Ovarian Cancer Observational Case-Control Study;Cancers;2023-12-20

2. Antineoplastics;Reactions Weekly;2023-09-23

3. PARPi Decreased Primary Ovarian Cancer Organoid Growth Through Early Apoptosis and Base Excision Repair Pathway;Cell Transplantation;2023-01

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3